Location-based prediction model for Crohn's disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies.
Chitinase 3-like 1 autoantibodies
Crohn’s disease
Disease progression
Enzyme-linked immunosorbent assay
Immunoglobulin subtypes
Ulcerative colitis
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 Nov 2023
14 Nov 2023
Historique:
received:
28
06
2023
revised:
03
10
2023
accepted:
02
11
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
ppublish
Résumé
Defective neutrophil regulation in inflammatory bowel disease (IBD) is thought to play an important role in the onset or manifestation of IBD, as it could lead to damage of the intestinal mucosal barrier by the infiltration of neutrophils in the inflamed mucosa and the accumulation of pathogens. Like neutrophils in the context of innate immune responses, immunoglobulin A (IgA) as an acquired immune response partakes in the defense of the intestinal epithelium. Under normal conditions, IgA contributes to the elimination of microbes, but in connection with the loss of tolerance to chitinase 3-like 1 (CHI3L1) in IBD, IgA could participate in CHI3L1-mediated improved adhesion and invasion of potentially pathogenic microorganisms. The tolerance brake to CHI3L1 and the occurrence of IgA autoantibodies to this particular target, the exact role and underlying mechanisms of CHI3L1 in the pathogenesis of IBD are still unclear. To determine the predictive potential of Ig subtypes of a novel serological marker, anti-CHI3L1 autoantibodies (aCHI3L1) in determining the disease phenotype, therapeutic strategy and long-term disease course in a prospective referral cohort of adult IBD patients. Sera of 257 Crohn's disease (CD) and 180 ulcerative colitis (UC) patients from a tertiary IBD referral center of Hungary (Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen) were assayed for IgG, IgA, and secretory IgA (sIgA) type aCHI3L1 by enzyme-linked immunosorbent assay using recombinant CHI3L1, along with 86 healthy controls (HCONT). The IgA type was more prevalent in CD than in UC (29.2% CHI3L1 is a novel neutrophil autoantigenic target in IBD. The consideration of antibody classes along with location-based prediction may transform the future of serology in IBD.
Sections du résumé
BACKGROUND
BACKGROUND
Defective neutrophil regulation in inflammatory bowel disease (IBD) is thought to play an important role in the onset or manifestation of IBD, as it could lead to damage of the intestinal mucosal barrier by the infiltration of neutrophils in the inflamed mucosa and the accumulation of pathogens. Like neutrophils in the context of innate immune responses, immunoglobulin A (IgA) as an acquired immune response partakes in the defense of the intestinal epithelium. Under normal conditions, IgA contributes to the elimination of microbes, but in connection with the loss of tolerance to chitinase 3-like 1 (CHI3L1) in IBD, IgA could participate in CHI3L1-mediated improved adhesion and invasion of potentially pathogenic microorganisms. The tolerance brake to CHI3L1 and the occurrence of IgA autoantibodies to this particular target, the exact role and underlying mechanisms of CHI3L1 in the pathogenesis of IBD are still unclear.
AIM
OBJECTIVE
To determine the predictive potential of Ig subtypes of a novel serological marker, anti-CHI3L1 autoantibodies (aCHI3L1) in determining the disease phenotype, therapeutic strategy and long-term disease course in a prospective referral cohort of adult IBD patients.
METHODS
METHODS
Sera of 257 Crohn's disease (CD) and 180 ulcerative colitis (UC) patients from a tertiary IBD referral center of Hungary (Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen) were assayed for IgG, IgA, and secretory IgA (sIgA) type aCHI3L1 by enzyme-linked immunosorbent assay using recombinant CHI3L1, along with 86 healthy controls (HCONT).
RESULTS
RESULTS
The IgA type was more prevalent in CD than in UC (29.2%
CONCLUSION
CONCLUSIONS
CHI3L1 is a novel neutrophil autoantigenic target in IBD. The consideration of antibody classes along with location-based prediction may transform the future of serology in IBD.
Identifiants
pubmed: 38075846
doi: 10.3748/wjg.v29.i42.5728
pmc: PMC10701337
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5728-5750Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Références
Arch Physiol Biochem. 2021 Jun;127(3):279-284
pubmed: 31295039
Pathog Glob Health. 2023 Dec;117(8):708-716
pubmed: 36562081
Clin Exp Immunol. 2005 May;140(2):343-8
pubmed: 15807860
Curr Opin Gastroenterol. 2010 Nov;26(6):554-63
pubmed: 20693891
Int J Biol Macromol. 2017 Apr;97:331-338
pubmed: 28093332
World J Gastroenterol. 2015 Jun 14;21(22):6952-64
pubmed: 26078573
Adv Clin Chem. 2013;60:187-208
pubmed: 23724745
World J Gastroenterol. 2011 Sep 7;17(33):3830-5
pubmed: 21987626
Nat Rev Rheumatol. 2021 Oct;17(10):585-595
pubmed: 34341562
Nat Rev Immunol. 2012 Dec;12(12):821-32
pubmed: 23103985
J Crohns Colitis. 2015 Oct;9(10):891-8
pubmed: 26188353
Int J Colorectal Dis. 2003 May;18(3):254-9
pubmed: 12673492
J Clin Immunol. 2010 Jan;30(1):10-6
pubmed: 20101521
Clin Chim Acta. 2020 Sep;508:170-178
pubmed: 32413402
Biomed Res Int. 2022 Mar 20;2022:3227957
pubmed: 35360517
J Crohns Colitis. 2010 Feb;4(1):7-27
pubmed: 21122488
Clin Immunol. 2013 Jun;147(3):151-4
pubmed: 23587745
Am J Respir Crit Care Med. 2010 Oct 1;182(7):918-28
pubmed: 20558631
Scand J Gastroenterol. 2018 Apr;53(4):379-389
pubmed: 29523023
Immunobiology. 2012 May;217(5):483-91
pubmed: 21601307
Gut. 2013 Oct;62(10):1505-10
pubmed: 24037875
Front Immunol. 2013 Sep 17;4:280
pubmed: 24062746
Clin Microbiol Infect. 2020 Oct;26(10):1411.e1-1411.e9
pubmed: 31972315
Pathobiology. 2016;83(5):228-42
pubmed: 27189062
J Microbiol Biotechnol. 2022 Jul 28;32(7):825-834
pubmed: 35791076
Gastrointest Endosc. 2004 Oct;60(4):505-12
pubmed: 15472670
PLoS One. 2017 Jan 18;12(1):e0170034
pubmed: 28099495
Immunobiology. 2016 Mar;221(3):399-411
pubmed: 26686909
J Crohns Colitis. 2019 Jul 25;13(7):894-904
pubmed: 30753386
Semin Nephrol. 2021 Sep;41(5):416-426
pubmed: 34916002
Therap Adv Gastroenterol. 2016 Jul;9(4):606-25
pubmed: 27366227
Metabolism. 2019 Jun;95:46-56
pubmed: 30935969
Surg Clin North Am. 2015 Dec;95(6):1105-22, v
pubmed: 26596917
J Clin Lab Anal. 2022 Sep;36(9):e24605
pubmed: 35837962
Allergy Asthma Proc. 2021 Nov 1;42(6):e167-e173
pubmed: 34871165
Int J Chron Obstruct Pulmon Dis. 2019 Jul 22;14:1611-1631
pubmed: 31413557
Inflamm Bowel Dis. 2017 Dec 19;24(1):78-92
pubmed: 29272479
Inflamm Intest Dis. 2016 Oct;1(3):135-145
pubmed: 29922669
Discov Med. 2022 Jan-Feb;33(168):41-49
pubmed: 36274212
Signal Transduct Target Ther. 2020 Sep 14;5(1):201
pubmed: 32929074
Front Immunol. 2022 Feb 10;13:760776
pubmed: 35222369
Curr Opin Gastroenterol. 2014 Jul;30(4):359-64
pubmed: 24811052
Clin Gastroenterol Hepatol. 2010 Apr;8(4):357-63
pubmed: 20096379
Mediators Inflamm. 2015;2015:628157
pubmed: 26582965
Immunobiology. 2013 Oct;218(10):1227-34
pubmed: 23706599
Scand J Gastroenterol. 2003 Jun;38(6):599-605
pubmed: 12825867
Therap Adv Gastroenterol. 2023 Mar 11;16:17562848231155987
pubmed: 36923488
Elife. 2021 Jun 10;10:
pubmed: 34110284
Int J Mol Sci. 2023 Mar 27;24(7):
pubmed: 37047273
Nature. 2007 Jul 26;448(7152):427-34
pubmed: 17653185
J Clin Immunol. 2001 Sep;21(5):303-9
pubmed: 11720003
Clin Immunol. 2019 Feb;199:12-17
pubmed: 30543919
J Dig Dis. 2017 Sep;18(9):495-503
pubmed: 28857501
PeerJ. 2023 May 1;11:e15341
pubmed: 37151293
Inflamm Res. 2006 Jun;55(6):221-7
pubmed: 16955240
Hum Genet. 2021 Sep;140(9):1299-1312
pubmed: 34185153
Cardiovasc Diabetol. 2009 Nov 23;8:61
pubmed: 19930630
Gut. 2006 Mar;55 Suppl 1:i16-35
pubmed: 16481629
J Rheumatol. 2002 Jul;29(7):1459-66
pubmed: 12136906
J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 2):e357-62
pubmed: 17725598
J Am Heart Assoc. 2016 Nov 4;5(11):
pubmed: 27815265
Inflamm Bowel Dis. 2009 Jan;15(1):100-13
pubmed: 18623167
J Am Heart Assoc. 2020 Mar 3;9(5):e014634
pubmed: 32114892
Folia Med Cracov. 2020;60(1):61-74
pubmed: 32658213
J Crohns Colitis. 2011 Apr;5(2):165-6
pubmed: 21453888
Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-9
pubmed: 2617184
J Am Soc Nephrol. 2017 Nov;28(11):3218-3226
pubmed: 28679671
PLoS One. 2018 Mar 28;13(3):e0194166
pubmed: 29590158
J Neurochem. 2023 Jun;165(6):772-790
pubmed: 37026513
Hum Immunol. 2010 Apr;71(4):407-13
pubmed: 20079790
J Crohns Colitis. 2010 Feb;4(1):28-62
pubmed: 21122489
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
Gut. 2006 Mar;55 Suppl 1:i1-15
pubmed: 16481628
J Pediatr Gastroenterol Nutr. 2022 Jul 1;75(1):48-51
pubmed: 35622011
Histopathology. 2010 Sep;57(3):371-83
pubmed: 20840668
J Crohns Colitis. 2019 Feb 1;13(2):144-164
pubmed: 30137275
Rheumatology (Oxford). 1999 Nov;38 Suppl 2:8-10
pubmed: 10646482
Arthritis Rheum. 1997 Jun;40(6):1115-25
pubmed: 9182922
J Dermatolog Treat. 2022 Jun;33(4):1967-1974
pubmed: 34369253
Mol Immunol. 2023 Apr;156:98-110
pubmed: 36921490
Genomics. 2021 Jul;113(4):1988-1998
pubmed: 33872704
J Hepatol. 2013 Sep;59(3):457-66
pubmed: 23639483
Clin Gastroenterol Hepatol. 2019 Jan;17(2):243-255
pubmed: 30196163
Osteoarthritis Cartilage. 2001 Apr;9(3):203-14
pubmed: 11300743
Biomed Res Int. 2019 Apr 23;2019:3950628
pubmed: 31179321
Aliment Pharmacol Ther. 2016 May;43(10):1069-79
pubmed: 26953251
J Clin Med. 2016 Dec 17;5(12):
pubmed: 27999328
JCI Insight. 2022 Sep 22;7(18):
pubmed: 35951428
J Reprod Immunol. 2009 Jan;79(2):183-7
pubmed: 19200605
Int J Biol Sci. 2022 May 21;18(9):3731-3746
pubmed: 35813465
Pathophysiology. 2018 Dec;25(4):253-262
pubmed: 30266339
Ann Allergy Asthma Immunol. 2022 Jun;128(6):682-688.e5
pubmed: 35342020
Hypertens Pregnancy. 2014 Nov;33(4):467-75
pubmed: 25068525
Nat Rev Immunol. 2021 Oct;21(10):680-686
pubmed: 34518662
Sleep Breath. 2022 Sep;26(3):1011-1022
pubmed: 34657273
Gastroenterol Res Pract. 2013;2013:683824
pubmed: 23762038
Int J Gen Med. 2022 Jun 28;15:5835-5841
pubmed: 35789773
Aliment Pharmacol Ther. 2011 Oct;34(8):941-8
pubmed: 21848856
Gastroenterology. 2006 Feb;130(2):398-411
pubmed: 16472595
Dig Dis. 2014;32(4):475-83
pubmed: 24969297
Am J Transl Res. 2022 Jun 15;14(6):4090-4096
pubmed: 35836859
PLoS Med. 2006 Aug;3(8):e297
pubmed: 16942393
J Crohns Colitis. 2015 Aug;9(8):659-68
pubmed: 25968583
Lab Invest. 2008 Aug;88(8):883-95
pubmed: 18490894
Nat Rev Gastroenterol Hepatol. 2014 Feb;11(2):88-98
pubmed: 24345891
Autoimmun Rev. 2014 Feb;13(2):163-77
pubmed: 24157629
Ann Allergy Asthma Immunol. 2019 Oct;123(4):404-405
pubmed: 31330242
Hepatology. 2005 Mar;41(3):422-33
pubmed: 15723320
Gut. 2006 Mar;55 Suppl 1:i36-58
pubmed: 16481630
Ann Palliat Med. 2021 May;10(5):5509-5519
pubmed: 34107703
Front Pharmacol. 2022 Mar 17;13:826471
pubmed: 35370755
PLoS One. 2017 Nov 3;12(11):e0187572
pubmed: 29099860
Am J Gastroenterol. 2009 Apr;104(4):993-1001; quiz 1002
pubmed: 19277033
Gut. 2006 Mar;55(3):426-31
pubmed: 16474109
Clin Exp Rheumatol. 2001 Nov-Dec;19(6):655-60
pubmed: 11791636
Clin Immunol. 2016 Apr;165:21-8
pubmed: 26948930
Rheumatology (Oxford). 1999 Jul;38(7):618-26
pubmed: 10461474
Shock. 2009 Oct;32(4):393-400
pubmed: 19197227
Dtsch Arztebl Int. 2016 Feb 5;113(5):72-82
pubmed: 26900160
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
J Atheroscler Thromb. 2015;22(3):257-64
pubmed: 25253160
Digestion. 2021;102(6):833-844
pubmed: 34518458
Clin Chim Acta. 2020 Dec;511:40-46
pubmed: 33002471
Crit Rev Clin Lab Sci. 2016 Dec;53(6):396-408
pubmed: 27187575
World J Gastrointest Pathophysiol. 2013 Aug 15;4(3):63-4
pubmed: 23946890
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174
Nat Commun. 2016 Sep 15;7:12752
pubmed: 27629921
Neurogastroenterol Motil. 2012 Jun;24(6):503-12
pubmed: 22583600
Exp Ther Med. 2019 Jan;17(1):423-431
pubmed: 30651816